title: Meglumine antimoniate-induced pancreatitis.
authors.forename: D
authors.initials: D
authors.lastname: Torrús
authors.forename: B
authors.initials: B
authors.lastname: Massa
authors.forename: V
authors.initials: V
authors.lastname: Boix
authors.forename: J
authors.initials: J
authors.lastname: Portilla
authors.forename: M
authors.initials: M
authors.lastname: Pérez-Mateo
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000276:immunology; D000208:Acute Disease; D000328:Adult; D000965:Antimony; D000981:Antiprotozoal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology; D007898:Leishmaniasis, Visceral / Q000188:drug therapy / Q000276:immunology; D008536:Meglumine / Q000009:adverse effects* / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D010195:Pancreatitis / Q000139:chemically induced*
chemical_list: D000981:Antiprotozoal Agents; D007166:Immunosuppressive Agents; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate; D000965:Antimony